INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
INSMED Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$95.29−0.98 (-1.02%)
Close on Oct 19, 2026
- Market cap
- $20.71B
- P/E (TTM)
- –
- Dividend yield
- –
INSMED Inc revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BRINSUPRI | $689.68M | $380.51M | $172.66M | $28.05M | $0 | – | $0 | – | – | – | – | – | 60.6% | – |
| ARIKAYCE external R&D expenses | $447.95M | $439.05M | $433.77M | $418.97M | $398.11M | – | $363.71M | – | – | – | – | – | 39.4% | +12.5% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $968.80M | $658.74M | $452.95M | $302.78M | $267.62M | $262.73M | $254.80M | $245.27M | $237.61M | $231.48M | $224.20M | $214.42M | 85.2% | +262.0% |
| International | $168.83M | $160.82M | $153.47M | $144.24M | $130.49M | – | $108.91M | – | – | – | – | – | 14.8% | +29.4% |
| Japan | – | – | – | – | $104.45M | $94.89M | $87.70M | $77.94M | $72.99M | $67.47M | $65.73M | $60.28M | – | – |
| Europe and rest of world | – | – | – | – | $26.04M | $23.41M | $21.21M | $19.75M | $18.01M | $16.55M | $15.28M | – | – | – |
From the segment and revenue-disaggregation notes of Insmed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.